Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests
2005; Wiley; Volume: 78; Issue: 6 Linguagem: Inglês
10.1016/j.clpt.2005.08.013
ISSN1532-6535
AutoresTherése Andersson, D. A. Flockhart, Daniel A. Goldstein, Shiew‐Mei Huang, Deanna L. Kroetz, Patrice M. Milos, Mark J. Ratain, Kenneth E. Thummel,
Tópico(s)Pharmacological Effects and Toxicity Studies
ResumoClinical Pharmacology & TherapeuticsVolume 78, Issue 6 p. 559-581 Commentary Drug-metabolizing enzymes: Evidence for clinical utility of pharmacogenomic tests Tommy Andersson PhD, Tommy Andersson PhD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashSearch for more papers by this authorDavid A. Flockhart MD, PhD, David A. Flockhart MD, PhD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashSearch for more papers by this authorDavid B. Goldstein PhD, David B. Goldstein PhD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashSearch for more papers by this authorShiew-Mei Huang PhD, Corresponding Author Shiew-Mei Huang PhD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashOffice of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993–0002 E-mail: [email protected]Search for more papers by this authorDeanna L. Kroetz PhD, Deanna L. Kroetz PhD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashSearch for more papers by this authorPatrice M. Milos PhD, Patrice M. Milos PhD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashSearch for more papers by this authorMark J. Ratain MD, Mark J. Ratain MD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashSearch for more papers by this authorKenneth Thummel PhD, Kenneth Thummel PhD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashSearch for more papers by this author Tommy Andersson PhD, Tommy Andersson PhD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashSearch for more papers by this authorDavid A. Flockhart MD, PhD, David A. Flockhart MD, PhD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashSearch for more papers by this authorDavid B. Goldstein PhD, David B. Goldstein PhD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashSearch for more papers by this authorShiew-Mei Huang PhD, Corresponding Author Shiew-Mei Huang PhD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashOffice of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993–0002 E-mail: [email protected]Search for more papers by this authorDeanna L. Kroetz PhD, Deanna L. Kroetz PhD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashSearch for more papers by this authorPatrice M. Milos PhD, Patrice M. Milos PhD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashSearch for more papers by this authorMark J. Ratain MD, Mark J. Ratain MD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashSearch for more papers by this authorKenneth Thummel PhD, Kenneth Thummel PhD Clinical Pharmacology, AstraZeneca, Mölndal, Sweden Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Ind Department of Biology (Galton Lab), University College London, London, United Kingdom Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md School of Pharmacy, University of California San Francisco, San Francisco, Calif Pharmacogenomics, Pfizer Global Research and Development, Groton, Conn University of Chicago, Chicago, Ill University of Washington, Seattle, WashSearch for more papers by this author First published: 07 December 2005 https://doi.org/10.1016/j.clpt.2005.08.013Citations: 23 This commentary was based on presentations made at a Food and Drug Administration/Johns Hopkins University/Pharmaceutical Research and Manufacturers of America educational workshop, September 13, 2004, Rockville, Md. The views presented in this article do not necessarily reflect those of the Food and Drug Administration. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1DiMasi, J. A., Hansen, R. W. and Graboswki, H. G. (2003). The price of innovation: new estimates of drug development costs. J Health Econ 22: 151–185. 2Gilbert, J., Henske, P. and Singh, A. (2003). In vivo Windhover Information: Norwalk (CT). Vol. 21, No. 10. 3Jenkins, J. K. (2004). Proceedings of the International Conference on Drug Development; 2004 Feb 25 Austin: The Conference: Austin, Tex. 4 FDA white paper. Innovation or stagnation: challenge and opportunity on the critical path to new medical products. (2004). Available from: URL: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html Accessed March 25, 2005 5 FDA strategic action plan. Protecting and advancing America's health: responding to new challenges and opportunities. (August 2003). Available from: URL: http://www.fda.gov/oc/mcclellan/strategic.html Accessed March 25, 2005 6 Guidance for industry. Pharmacogenomic data submissions. (Posted March 22, 2005). Available from: URL: http://www.fda.gov/cder/guidance/6400fnl.pdf Accessed March 25, 2005 7 Guidance for industry. Attachment to guidance on pharmacogenomic data submissions: examples of voluntary submissions or submissions required under 21 CFR 312, 314, or 601. (Posted March 22, 2005). Available from: URL: http://www.fda.gov/cder/guidance/6400fnlAttch.pdf Accessed March 25, 2005 8Salerno, R. A. and Lesko, L. J. (2004). Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 5: 503–505. 9Leighton, J. K., DeGeorge, J., Jacobson-Kram, D., MacGregor, J., Mendrick, D. and Worobec, A. (2004). Pharmacogenomic data submissions to the FDA: non-clinical case studies. Pharmacogenomics 5: 507–511. 10Ruaño, G., Collins, J. M., Dorner, A. J., Wang, S.-J., Guerciolini, R. and Huang, S.-M. (2004). Pharmacogenomic data submissions to the FDA: clinical pharmacology case studies. Pharmacogenomics 5: 513–517. 11Trepicchio, W. L., Williams, G. A., Essayan, D., Hall, S. T., Harty, L. C. and Shaw, P. M., et al. (2004). Pharmacogenomic data submissions to the FDA: clinical case studies. Pharmacogenomics 5: 519–524. 12 FDA/Drug Information Association pharmacogenomics workshop. Co-development of drug, biological and device products; (2004 Jul 29); Arlington, Va. Available from: URL: http://www.diahome.org/Content/Events/04040.pdf Accessed March 25, 2005 13 Drug-diagnostic co-development concept paper. (April 2005). Available from: URL: http://www.fda.gov/cder/genomics/pharmacoconceptfn.pdf Accessed April 22 14Frueh, F. W., Huang, S.-M. and Lesko, L. J. (2004). Regulatory acceptance of toxicogenomics data. Environ Health Perspect 112: A663–A664. 15Lesko, L. J. and Woodcock, J. (2004). Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat Rev Drug Discov 3: 763–770. 16Huang S-M, Lesko LJ. Application of pharmacogenomics in clinical pharmacology—in part I: molecular medicine, correlation between genes, diseases and biopharmaceuticals. In: J Knablein, RH Muller, editors. Modern biopharmaceuticals: design, development and optimization. Hoboken (NJ): Wiley-VCH. In press. 17Huang, S.-M., Regulatory issues in genotyping metabolizing enzymes—CDER perspective. Presented at the FDA/Pharmaceutical Research and Manufacturers of America/Johns Hopkins University educational workshop; 2004 Sep 13–14 (2005 Sep 13–14); Rockville, Md. Available from: http://www.fda.gov/cder/offices/ocpb/workshops.htm Accessed June 2, 2005 18 ICH E5. Guidance on ethnic factors in the acceptability of foreign clinical data. (1998). Available from: URL: http://www.fda.gov/cder/guidance/2293fnl.pdf Accessed March 26, 2005 1918a Guidance for industry. E5—ethnic factors in the acceptability of foreign clinical data. Questions and answers. (2004). Available from: URL: http://www.fda.gov/cder/guidance/6200fnl.pdf Accessed March 26, 2005 20 Clinical pharmacology and biopharmaceutics review template. Issued April 27, 2004. (Posted June 24, 2004). Available from: URL: http://www.fda.gov/cder/mapp/4000.4.pdf Accessed March 26, 2005 21 Guidance for industry. Exposure-response relationships—study design, data analysis, and regulatory applications. (Posted May 2003). Available from: URL: http://www.fda.gov/cder/guidance/5341fnl.pdf Accessed March 26, 2005 22 Labeling information. (2004). Available from: URL: http://www.fda.gov/cder/approval/index.htm or http://pdrel.thomsonhc.com/pdrel/librarian (Physicians' desk reference). 23Chow, M., Huang, S.-M., Sahajwalla, C. and Lesko, L. J. (2003). An informal survey of pharmacogenetics/pharmacogenomics (PGTX) in a sample of INDs and NDAs [abstract]. Clin Pharmacol Ther 73: P33. 24 Human cytochrome P450 (CYP) nomenclature committee Web site. (2005). Available from: URL: http://www.imm.ki.se/cypalleles/ Accessed March 26, 2005 25Milos, P. Special considerations for individual metabolic biomarkers: CYP2C9. Proceedings of the FDA/Pharmaceutical Research and Manufacturers of America/Johns Hopkins University educational workshop; (2004 Sep 13–14); Rockville, Md. Available from: URL: http://www.fda.gov/cder/offices/ocpb/workshops.htm Accessed June 2, 2005 26Goldstein, J. A. and de Morais, S. M. (1994). Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4: 285–299. 27Rettie, A. E., Wienkera, L. C., Gonzalez, F. T., Trager, W. F. and Korzekwa, K. R. (1994). Impaired (S)-warfarin metabolism catalyzed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4: 39–42. 28Sullivan-Klose, T. H., Ghanayem, B. I., Bell, D. A., Zhang, Z. Y., Kaminsky, L. S. and Shenfield, G. M., et al. (1996). The role of the CYP2C9 Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6: 341–349. 29Imai, J., Ieiri, I., Mamiya, K., Miyahara, S., Furuumi, H. and Nanba, E., et al. (2000). Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 10: 85–89. 30Dickmann, L. J., Rettie, A. E., Kneller, M. B., Kim, R. B., Wood, A. J. and Stein, C. M., et al. (2001). Identification and functional characterization of a new CYP2C9 variant (CYP2C9 *5) expressed among African Americans. Mol Pharmacol 60: 382–387. 31Kidd, R. S., Curry, T. B., Gallagher, S., Edeki, T., Blaisdell, J. and Goldstein, J. A. (2001). Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11: 803–808. 32Aithal, G. P., Day, C. P., Kesteven, P. J. and Daly, A. K. (1999). Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353: 717–719. 33Tabrizi, A. R., Zehnbauer, B. A., Borecki, I. B., McGrath, S. D., Buchman, T. G. and Freeman, B. D. (2002). The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 194: 267–273. 34Higashi, M. K., Veenstra, D. L., Kondo, L. M., Wittkowsky, A. K., Srinouanprachanh, S. L. and Farin, F. M., et al. (2002). Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287: 1690–1698. 35Shintani, M., Ieiri, I., Inoue, K., Mamiya, K., Ninomiya, H. and Tashiro, N., et al. (2001). Genetic polymorphisms and functional characterization of the 5′ flanking region of the human CYP2C9 gene: in vitro and in vivo studies. Clin Pharmacol Ther 70: 175–182. 36Andersson, T. Special considerations for individual metabolic biomarkers: CYP2C19. In: Proceedings of the FDA/Pharmaceutical Research and Manufacturers of America/Johns Hopkins University educational workshop; (2004 Sep 13–14); Rockville, Md. Available from: URL: http://www.fda.gov/cder/offices/ocpb/workshops.htm Accessed June 2, 2005 37Flockhart, D. Special considerations for individual metabolic biomarkers: CYP2D6. In: Proceedings of the FDA/Pharmaceutical Research and Manufacturers of America/Johns Hopkins University educational workshop; (2004 Sep 13–14); Rockville, Md. Available from: URL: http://www.fda.gov/cder/offices/ocpb/workshops.htm Accessed June 2, 2005 38Ratain, M. Special considerations for individual metabolic biomarkers: UGT1A1. In: Proceedings of the FDA/Pharmaceutical Research and Manufacturers of America/Johns Hopkins University educational workshop; (2004 Sep 13–14); Rockville, Md. Available from: URL: http://www.fda.gov/cder/offices/ocpb/workshops.htm Accessed June 2, 2005 39Küpfer, A. and Preisig, R. (1984). Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26: 753–759. 40Goldstein, J. A., Ishizaki, T., Chiba, K., Morais, S. M. F., Bell, D. and Krahn, P. M., et al. (1997). Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasians, Saudi Arabians and American black populations. Pharmacogenetics 7: 59–64. 41Meier, U. T. and Meyer, U. A. (1987). Genetic polymorphism of human cytochrome P-450/(S)-mephenytoin 4-hydroxylase. Studies with human autoantibodies suggest a functionally altered cytochrome P-450 isozyme as cause of the genetic deficiency. Biochemistry 26: 8466–8474. 42Wrighton, S. A., Stevens, J. C., Becker, G. W. and VandenBranden, M. (1993). Isolation and characterization of human liver cytochrome P450 2C19; correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 306: 240–245. 43Blaisdell, J., Mohrenweiser, H., Jackson, J., Ferguson, S., Coulter, S. and Chanas, B., et al. (2002). Identification and functional characterization of new potentially defective alleles of human CYP2C19. Pharmacogenetics 12: 703–711. 44Desta, Z., Zhao, X., Shin, J. G. and Flockhart, D. A. (2002). Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet 41: 913–958. 45Inaba, T., Jorge, L. F. and Arias, T. D. (1988). Mephenytoin hydroxylation in the Cuna Amerindians of Panama. Br J Clin Pharmacol 25: 75–79. 46Kaneko, A., Laneko, O., Taleo, G., Bjorkman, A. and Kobayakawa, T. (1999). High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet 349: 921–922. 47Sim, S. C. M., Aklillu, E., Edwards, R. J., Ahlberg, S., Bertilsson, L. and Ingelman-Sundberg, M. (2004). Proceedings of the International Symposium on Microsomes and Drug Oxidations; 2004 Jul 4–9 Mainz: The Symposium: Mainz, Germany. 48Ferguson, R. J., De Morais, S. M. F., Benhamou, S., Bouchardy, C., Blaisdell, J. and Ibeanu, G., et al. (1998). A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 284: 356–361. 49Ibeanu, G. C., Blaisdell, J., Ferguson, R. J., Ghanayem, B. I., Brosen, K. and Benhamou, S., et al. (1999). A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther 290: 635–640. 50Ibeanu, G. C., Blaisdell, J., Ghanayem, B. I., Beyeler, C., Benhamou, S. and Bouchardy, C., et al. (1998). An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 8: 129–135. 51Ibeanu, G. C., Goldstein, J. A., Meyer, U., Benhamou, S., Bouchardy, C. and Dayer, P., et al. (1998). Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther 286: 1490–1495. 52Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T. and Kitareewan, S., et al. (1994). Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743–1752. 53Hoskins, J. M., Shenfield, G. M. and Gross, A. S. (1998). Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population [published erratum appears in Br J Clin Pharmacol 1999;4:603]. Br J Clin Pharmacol 46: 499–504. 54Andersson, T., Regårdh, C. G., Dahl-Puustinen, M. L. and Bertilsson, L. (1990). Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 12: 415–416. 55Chang, M., Tybring, G., Dahl, M. L., Gotharson, E., Sagar, M. and Seensalu, R., et al. (1995). Interphenotype differences in disposition and effect on gastrin levels of omeprazole—suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 39: 511–518. 56Ieiri, I., Kubota, T., Urae, A., Kimura, M., Wada, Y. and Mamiya, K., et al. (1996). Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19m1 in exon 5 and CYP2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 59: 647–653. 57Andersson, T., Holmberg, J., Röhss, K. and Walan, A. (1998). Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 45: 369–375. 58Katsuki, H., Nakamura, C., Arimori, K., Fujiyama, S. and Nakano, M. (1997). Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects. Eur J Clin Pharmacol 52: 391–396. 59Ishizaki, T., Sohn, D. R., Kobayashi, K., Chiba, K., Lee, K. H. and Shin, S. G., et al. (1994). Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 16: 214–215. 60Wedlund, P. J. (2000). The CYP2C19 enzyme polymorphism. Pharmacology 61: 174–183. 61Venkatakrishnan, K., Greenblatt, D. J., von Moltke, L. L., Schmider, J., Harmatz, J. S. and Shader, R. I. (1998). Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 38: 112–121. 62Nielsen, K. K., Flinois, J. P., Beaune, P. H. and Brosen, K. (1996). The biotransformation of clomipramine in vitro, identification of the cytochrome P450s responsible for the separate metabolic pathways. J Pharmacol Exp Ther 277: 1659–1664. 63Koyama, E., Tanaka, T., Chiba, K., Kawakatsu, S., Morinobu, S. and Totsuka, S., et al. (1996). Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4′-hydroxylation status in Japanese depressive patients. J Clin Psychopharmacol 16: 286–293. 64Koyama, E., Chiba, K., Tani, M. and Ishizaki, T. (1997). Reappraisal of human CYP450 isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYP450s. J Pharmacol Exp Ther 281: 1199–1210. 65Eap, C. B., Bender, S., Gastpar, M., Fischer, W., Haarmann, C. and Powell, K., et al. (2000). Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. Ther Drug Monit 22: 209–214. 66Fukuda, T., Yamamoto, I., Nishida, Y., Zhou, Q., Ohno, M. and Takada, K., et al. (1999). Effect of the CYP2D6*10 genotype on venlafaxine pharmacokinetics in healthy adult volunteers. Br J Clin Pharmacol 47: 450–453. 67Morinobu, S., Tanaka, T., Kawakatsu, S., Totsuka, S., Koyama, E. and Chiba, K., et al. (1997). Effects of genetic defects in the CYP2C19 gene on the N-demethylation of imipramine, and clinical outcome of imipramine therapy. Psychiatry Clin Neurosci 51: 253–257. 68Glassman, A. H., Perel, J. M., Shostak, M., Kantor, S. J. and Fleiss, J. L. (1977). Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 34: 197–204. 69Kantor, S. J., Glassman, A. H., Bigger, J. T., Jr, Perel, J. M. and Giardina, E. V. (1978). The cardiac effects of therapeutic plasma concentrations of imipramine. Am J Psychiatry 135: 534–538. 70Caccia, S. (1998). Metabolism of the newer antidepressants: an overview of the pharmacological and pharmacokinetic implications. Clin Pharmacokinet 34: 281–302. 71Madsen, H., Hansen, T. S. and Brosen, K. (1996). Imipramine metabolism in relation to the sparteine oxidation polymorphism: a family study. Pharmacogenetics 6: 513–519. 72Kirchheiner, J., Brosen, K., Dahl, M. L., Gram, L. F., Kasper, S. and Roots, I., et al. (2001). CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104: 173–192. 73Liu, Z. Q., Cheng, Z. N., Huang, S. L., Chen, X. P., Ou-Yang, D. S. and Jiang, C. H., et al. (2001). Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects. Br J Clin Pharmacol 52: 96–99. 74Sindrup, S. H., Brosen, K., Hansen, M. G., Aaes-Jorgensen, T., Overo, K. F. and Gram, L. F. (1993). Pharmacokinetics o citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 15: 11–17. 75Wang, J. H., Liu, Z. Q., Wang, W., Chen, X. P., Shu, Y. and He, N., et al. (2001). Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 70: 42–47. 76Knodell, R. G., Dubey, R. K., Wilkinson, G. R. and Guengerich, F. P. (1988). Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther 245: 845–849. 77Kaminsk
Referência(s)